(Alliance News) - Hutchmed (China) Ltd on Friday said it initiated the registration stage of the phase 2/3 clinical trial for sovleplenib, its warm antibody autoimmune hemolytic anemia treatment.
Shares in Hutchmed were down 7.6% to 254.50 pence each in London on Friday morning.
wAIHA is an autoimmune disorder that can lead to anemia and has limited treatment options, Hutchmed said.
The Hong Kong-based developer of treatments for cancer and immunological diseases said this follows positive data from the proof-of-concept phase 2 stage of the trial and subsequent consultation with the China National Medical Products Administration.
If positive, Hutchmed said the data from the trial may be used to support a future new drug application filing.
The first phase 3 patient received their initial dose on Wednesday. Hutchmed said 21 patients have been enrolled in the study so far and approximately 90 more patients are expected to be enrolled to this registration stage.
By Greg Rosenvinge, Alliance News senior reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Hutchmed (HCM)